This invention provides smooth muscle cell proliferation inhibitors of
formula I having the structure ##STR00001## wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are each,
independently, acyl of 2 7 carbon atoms, haloacyl of 2 7 carbon atoms,
nitroacyl of 2 7 carbon atoms, cyanoacyl of 2 7 carbon atoms,
trifluoromethylacyl of 3 8 carbon atoms, benzoyl, or --SO.sub.3H; R.sup.9
is hydrogen, CN, NO.sub.2, halo, CF.sub.3, alkyl of 1 6 carbon atoms, or
alkoxy of 1 6 carbon atoms; R.sup.10 is hydrogen, --NO.sub.2,
--NHR.sup.11, --NHR.sup.13, --N(R.sup.13).sub.2, --NCH.sub.3R.sup.13,
--NHCO.sub.2alkyl, wherein the alkyl moiety contains 1 6 carbon atoms,
alkylsulfonamide of 1 to 4 carbon atoms, ##STR00002## Z is O or S;
R.sup.11 is an .alpha.-amino acid in which the .alpha. carboxyl group
forms an amide with the nitrogen of R.sup.10, wherein if said amino acid
is glutamic acid or aspartic acid, the non-.alpha. carboxylic acid is an
alkyl ester in which the alkyl moiety contains from 1 6 carbon atoms;
R.sup.12 is hydrogen, CN, NO.sub.2, halo, CF.sub.3, alkyl of 1 6 carbon
atoms, alkoxy of 1 6 carbon atoms, acyl of 2 7 carbon atoms, or benzoyl;
R.sup.13 is hydrogen, acyl of 2 7 carbon atoms, haloacyl of 2 7 carbon
atoms, nitroacyl of 2 7 carbon atoms, cyanoacyl of 2 7 carbon atoms,
trifluoromethylacyl of 3 8 carbon atoms, or benzoyl; or a
pharmaceutically acceptable salt thereof.
